Triptorelin

Triptorelin

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Strong

FDA Approval Scope

U.S. FDA approval is formulation-, product-, indication-, and population-specific: TRELSTAR (triptorelin pamoate) for advanced prostate cancer; TRIPTODUR (triptorelin) for central precocious puberty in patients aged 2 years and older.

At a Glance

A synthetic GnRH agonist with product-specific U.S. approvals: TRELSTAR for advanced prostate cancer and TRIPTODUR for central precocious puberty in patients aged 2 years and older.

Plain English

Researchers study Triptorelin because continuous GnRH-agonist exposure suppresses the reproductive hormone axis. Product, formulation, population, dosing, safety, and indication must remain distinct: the listed U.S. labels cover TRELSTAR for advanced prostate cancer and TRIPTODUR for central precocious puberty.

Overview

Triptorelin is a GnRH agonist with a D-tryptophan substitution at position 6. Its U.S. approval scope must be stated by product: TRELSTAR is triptorelin pamoate for palliative treatment of advanced prostate cancer, and TRIPTODUR is triptorelin for central precocious puberty. Evidence and dosing must not be transferred across salts, depot products, routes, or indications.

Research Summary

The retained literature and official labels must remain product-, population-, indication-, and formulation-specific. The distinct U.S. product indications are advanced prostate cancer for TRELSTAR and central precocious puberty for TRIPTODUR. Findings from one indication or formulation do not establish efficacy, safety, or dosing for another.

Research Areas

  • Prostate cancer (androgen deprivation)
  • Central precocious puberty

Safety & Risks

Serious Risks

  • For TRELSTAR in advanced prostate cancer, distinguish the initial adult testosterone flare from other risks.
  • For TRIPTODUR in pediatric CPP, distinguish transient pubertal signs from adult prostate-cancer risks.
  • Follow the current applicable product label.

Reported Side Effects

  • Product- and population-specific; follow the current applicable product label.
United States
Product-, jurisdiction-, and indication-specific; consult the current official label.
United Kingdom
Product-, jurisdiction-, and indication-specific; consult the current official label.
Australia
Product-, jurisdiction-, and indication-specific; consult the current official label.
Canada
Product-, jurisdiction-, and indication-specific; consult the current official label.

Citations & Sources